Population-based screening - The difficulty of how to do more good than harm and how to achieve it

Swiss Medical Weekly

Volumn 140, Issue SEPTEMBER, 2010, Pages

  Zwahlen, Marcel ^a   Low, Nicola ^a   Borisch, Bettina ^b   Egger, Matthias ^a   Künzli, Nino ^f   Obrist, Reto ^e   Paccaud, Fred ^c,d   Zybach, Ursula ^g   Probst Hensch, Nicole M ^f  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d Swiss School of Public Health Plus   (Switzerland)

^e University of Basel ^*  (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

^g President Swiss Society for Public Health   (Switzerland)

Author keywords

Biomedical; Mass screening; Switzerland; Technology assessment

Indexed keywords

HFE PROTEIN; TRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; BREAST CANCER; CANCER SCREENING; CHRONIC DISEASE; COLORECTAL CANCER; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HEALTH CARE SYSTEM; HEMOCHROMATOSIS; HUMAN; MASS SCREENING; MORTALITY; NEWBORN SCREENING; OCCULT BLOOD; PROSTATE CANCER; PSEUDOMONAS AERUGINOSA; REVIEW; SWITZERLAND; UTERINE CERVIX CANCER;

EID: 84855938570     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2010.13061     Document Type: Review

References (81)

1. Gray JAM, Patnick J, Blanks RG. Maximising benefit and minimising harm of screening. BMJ. 2008;336:480-3. (Pubitemid 351347413)
2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and Prostate- Cancer Mortality in a Randomized European Study. N Engl J Med. 2009;360:1320-8.
3. Andriole GL, Grubb RL, III, Buys SS, et al. Mortality Results from a Randomized Prostate-Cancer Screening Trial. N Engl J Med. 2009;360:1310-9.
4. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 1999;38:83-91. (Pubitemid 29052946)
5. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59:311-8. (Pubitemid 38509764)
6. Sandblom G, Varenhorst E, Lofman O, et al. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol. 2004;46:717-23. (Pubitemid 39488400)
7. Ilic D, O'Connor D, Green S, et al. Screening for prostate cancer. Cochrane. Database.Syst.Rev 2006;3:CD004720.
8. Kwiatkowski M, Huber A, Recker F. PSA-Screening verringert Sterblichkeit um 20%. Schweiz Ärztezeitung. 2009;90:514.
9. Strebel U. Kommentar zum Artikel "PSA-Screening verringert Sterblichkeit um 20%". Schweiz Ärztezeitung. 2009;90:751.
10. Bumbacher H. Entgegnung zum Artikel "PSA-Screening verringert Sterblichkeit um 20%". Schweiz Ärztezeitung. 2009;90:752.
11. Paky A. Männer über 55: hopp, hopp zum PSA-Test... sonst sterbt ihr. Schweiz Ärztezeitung. 2009;90:753-4.
12. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:273S-309S.
13. Boyle P, Brawley OW. Prostate Cancer: Current Evidence Weighs Against Population Screening. CA: A Cancer Journal for Clinicians 2009;59:220-4.
14. Holmberg L. Prostate Cancer Screening: The Need For Problem-Solving that Puts Men's Interests First. Eur Urol. 2009;56:34-7.
15. Barry MJ. Screening for Prostate Cancer - The Controversy That Refuses to Die. N Engl J Med. 2009;360:1351-4.
16. Stark JR, Mucci L, Rothman KJ, et al. Prostate cancer screening: the controversy continues. BMJ. 2009;339:784-6.
17. Brawley OW. Prostate Cancer Screening; Is This a Teachable Moment? J Natl Cancer Inst. 2009;101:1295-7.
18. Wilson JMG, Jungner AG. Principles and practice of screening for disease. World Health Organization. 34, 1-163. 1968. Geneva. Public Health Papers.
19. Raffle AE, Gray JAM. Screening: evidence and practice. New York: Oxford University Press, 2007.
20. t' Veer LJ, Esserman LJ, Linn S, et al. Evaluation of the effect of screening on the detection of good and poor prognosis breast cancers. ASCO Meeting Abstracts 2009;27:1525.
21. Ikeda DM, Andersson I, Wattsgard C, et al. Interval carcinomas in the Malmo Mammographic Screening Trial: radiographic appearance and prognostic considerations. AJR Am J Roentgenol. 1992;159:287-94.
22. Ciatto S, Visioli C, Paci E, et al. Breast density as a determinant of interval cancer at mammographic screening. Br J Cancer. 2004;90:393-6. (Pubitemid 38250634)
23. Esserman L, Shieh Y, Thompson I. Rethinking Screening for Breast Cancer and Prostate Cancer. JAMA. 2009;302:1685-92.
24. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ. 2004;328:921-4. (Pubitemid 38496981)
25. Zahl PH, Maehlen J, Welch HG. The Natural History of Invasive Breast Cancers Detected by Screening Mammography. Arch Intern Med. 2008;168:2311-6.
26. Zahl PH, Jorgensen KJ, Maehlen J et al. Biases in estimates of overdetection due to mammography screening. Lancet Oncol. 2008;9:199-201. (Pubitemid 351722941)
27. Barry MJ, Mulley AJ Jr. Why Are a High Overdiagnosis Probability and a Long Lead Time for Prostate Cancer Screening So Important? J Natl Cancer Inst. 2009;101:362-3.
28. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostatespecific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981-90. (Pubitemid 34814727)
29. Juffs HG, Tannock IF. Screening trials are even more difficult than we thought they were. J Natl Cancer Inst. 2002;94:156-7. (Pubitemid 34162743)
30. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. 2002;94:167-73. (Pubitemid 34162750)
31. Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet. 2001;358:1340-2. (Pubitemid 33016501)
32. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane.Database.Syst.Rev 2009;CD001877.
33. Nelson HD, Tyne K, Naik A et al. Screening for Breast Cancer: An Update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:727-37.
34. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103:1541-9. (Pubitemid 351813919)
35. Koliopoulos G, Arbyn M, Martin-Hirsch P, et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007;104:232-46. (Pubitemid 46054137)
36. Franceschi S, Cuzick J, Herrero R et al. EUROGIN 2008 roadmap on cervical cancer prevention. Int J Cancer. 2009;125:2246-55.
37. Abrahamsson PA, Artibani W, Chapple CR, et al. European Association of Urology position statement on screening for prostate cancer. Eur Urol. 2009;56:270-1.
38. Coffield AB, Maciosek MV, McGinnis JM, et al. Priorities among recommended clinical preventive services. Am J Prev Med. 2001;21:1-9. (Pubitemid 32552000)
39. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. JNCI Cancer Spectrum 2009;101:1412-22.
40. Gray JA. New concepts in screening. Br J Gen Pract. 2004;54:292-8. (Pubitemid 38461156)
41. Gray M. Problems of evidence-based patient choice in screening programmes. Z Arztl Fortbild Qualitatssich. 2006;100:494-9. (Pubitemid 44757224)
42. Shapiro S, Coleman EA, Broeders M, et al. Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. Int J Epidemiol. 1998;27:735-42.
43. European Commission. European guidelines for quality assurance in mammography screening - Third edition. Perry, N, Broeders, M., de Wolf, C., Törnberg, S., and Schouten, J. 1-366. 2001. Brussels, Luxembourg, Office for Official Publications of the European Communities.
44. Bulliard JL, De Landtsheer JP, Levi F. Results from the Swiss mammography screening pilot programme. Eur J Cancer. 2003;39:1761-9. (Pubitemid 36897614)
45. Bulliard JL, De Landtsheer JP, Levi F. Reattendance in the Swiss mammography screening pilot programme. J Med Screen. 2004;11:59-64. (Pubitemid 38829882)
46. Bulliard JL, De Landtsheer JP, Levi F. Profile of women not attending in the Swiss Mammography Screening Pilot Programme. Breast. 2004;13:284-9. (Pubitemid 39172728)
47. Lipkus IM, Hollands JG. The visual communication of risk. J Natl Cancer Inst Monogr. 1999;149-63.
48. Thornton H, Edwards A, Baum M. Women need better information about routine mammography. BMJ. 2003;327:101-3. (Pubitemid 36836464)
49. Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N Engl J Med. 2003;348:1672-80. (Pubitemid 36459474)
50. Weller DP, Patnick J, McIntosh HM, et al. Uptake in cancer screening programmes. Lancet Oncol. 2009;10:693-9.
51. Slaytor EK, Ward JE. How risks of breast cancer and benefits of screening are communicated to women: analysis of 58 pamphlets. BMJ. 1998;317:263-4. (Pubitemid 28334155)
52. Chamot E, Perneger TV. Misconceptions about efficacy of mammography screening: a public health dilemma. J Epidemiol Community Health. 2001;55:799-803. (Pubitemid 32980459)
53. Domenighetti G, D'Avanzo B, Egger M, et al. Women's perception of the benefits of mammography screening: Population based survey in four countries. Intl J Epidemiol. 2003;32:816-21. (Pubitemid 37304647)
54. Osterlie W, Solbjor M, Skolbekken JA, et al. Challenges of informed choice in organised screening. J Med Ethics. 2008;34:e5.
55. Gigerenzer G, Edwards A. Simple tools for understanding risks: from innumeracy to insight. BMJ. 2003;327:741-4. (Pubitemid 37176763)
56. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, et al. Helping Doctors and Patients Make Sense of Health Statistics. Psychological Science In The Public Interest. 2008;8:53-96.
57. Khoury MJ, McBride CM, Schully SD, et al. The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med. 2009;11:559-67.
58. Burke W, Coughlin SS, Lee NC, et al. Application of population screening principles to genetic screening for adult-onset conditions. Genet Test. 2001;5:201-11. (Pubitemid 34066163)
59. Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med. 2003;348:50-8. (Pubitemid 36026347)
60. Rogowski WH, Grosse SD, Khoury MJ. Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet. 2009;10:489-95.
61. Khoury MJ, Feero WG, Reyes M, et al. The genomic applications in practice and prevention network. Genet Med. 2009;11:488-94.
62. Khoury MJ, Berg A, Coates R, et al. The evidence dilemma in genomic medicine. Health Aff. (Millwood.) 2008;27:1600-11.
63. Rogowski WH, Grosse SD, Khoury MJ. Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet. 2009;10:489-95.
64. Zlotogora J, Carmi R, Lev B, et al. A targeted population carrier screening program for severe and frequent genetic diseases in Israel. Eur J Hum Genet. 2009;17:591-7.
65. Wilcken B. Cystic fibrosis: refining the approach to newborn screening. J Pediatr. 2009;155:605-6.
66. Sims EJ, Mugford M, Clark A, et al. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet. 2007;369:1187-95. (Pubitemid 46546435)
67. Balfour-Lynn IM. Newborn screening for cystic fibrosis: evidence for benefit. Arch Dis Child. 2008;93:7-10.
68. Castellani C, Southern KW, Brownlee K, et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros. 2009;8:153-73.
69. Bodamer OA, Hoffmann GF, Lindner M. Expanded newborn screening in Europe 2007. J Inherit Metab Dis. 2007;30:439-44. (Pubitemid 47377039)
70. Hogarth DK, Rachelefsky G. Screening and familial testing of patients for alpha 1-antitrypsin deficiency. Chest. 2008;133:981-8. (Pubitemid 351536876)
71. Senn O, Russi EW, Imboden M, et al. alpha1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants. Eur Resp J. 2005;26:909-17. (Pubitemid 41632051)
72. Thelin T, Sveger T, McNeil TF. Primary prevention in a high-risk group: smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD). Acta Paediatr. 1996;85:1207-12. (Pubitemid 26346017)
73. Allen KJ. Population genetic screening for hereditary haemochromatosis: are we a step closer? Med J Aust. 2008;189:300-1.
74. Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular Disease Risk Prediction With and Without Knowledge of Genetic Variation at Chromosome 9p21.3. Ann Intern Med. 2009;150:65-72.
75. Lango H, Palmer CN, Morris AD, et al. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes. 2008;57:3129-35.
76. van Hoek M, Dehghan A, Witteman JC, et al. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes. 2008;57:3122-8.
77. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359:2220-32.
78. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37:120-32. (Pubitemid 351228620)
79. Chao S, Roberts JS, Marteau TM, et al. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord. 2008;22:94-7. (Pubitemid 351651404)
80. Jonsson E, Banta HD, Henshall C, et al. Summary report of the ECHTA/ ECAHI project. European Collaboration for Health Technology Assessment/ Assessment of Health Interventions. Int J Technol Assess Health Care. 2002;18:218-37.
81. Bassett K, Lee PM, Green CJ, et al. Triple-marker screening in British Columbia: current practice, future options. Fletcher, G. 2000. Vancouver, British Columbia., Office of Health Technology Assessment, Centre for Health Services and Policy Research, University of British Columbia (BCOHTA).